The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress

Journal of Pharmacological and Toxicological Methods

Volumn 81, Issue , 2016, Pages 15-20

  Colatsky, Thomas ^a   Fermini, Bernard ^b   Gintant, Gary ^c   Pierson, Jennifer B ^d   Sager, Philip ^e   Sekino, Yuko ^f   Strauss, David G ^a   Stockbridge, Norman ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b PFIZER INC   (United States)

^c ABBVIE INC   (United States)

^d ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

CiPA; In silico model; Ion channel; Myocyte; Proarrhythmia

Indexed keywords

ASTEMIZOLE; AZIMILIDE; BEPRIDIL; CHLORPROMAZINE; CISAPRIDE; CLARITHROMYCIN; CLOZAPINE; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DOMPERIDONE; DROPERIDOL; IBUTILIDE; ION CHANNEL; LORATADINE; METOPROLOL; MEXILETINE; NIFEDIPINE; NITRENDIPINE; ONDANSETRON; PIMOZIDE; QUINIDINE; RANOLAZINE; RISPERIDONE; SOTALOL; TAMOXIFEN; TERFENADINE; VANDETANIB; VERAPAMIL;

ARTICLE; CANADA; DRUG MECHANISM; ELECTROPHYSIOLOGY; HEALTH CARE; HEART PROARRHYTHMIA; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; JAPAN; MUSCLE CELL; NATIONAL HEALTH SERVICE; QT PROLONGATION; REPOLARIZATION; ANIMAL; CARDIAC MUSCLE CELL; CHEMICALLY INDUCED; COMPUTER SIMULATION; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; PATHOPHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; STEM CELL; TORSADE DES POINTES;

ANIMALS; ARRHYTHMIAS, CARDIAC; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; HUMANS; ION CHANNELS; MYOCYTES, CARDIAC; STEM CELLS; TORSADES DE POINTES;

EID: 84977593290     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2016.06.002     Document Type: Article

References (40)

1. Anonymous, International conference on harmonisation; guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; availability. Notice. Federal Register 70 (2005), 61133–61134 http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
2. Anonymous, International conference on harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Federal Register 70 (2005), 61134–61135 http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
3. Asakura, K., Hayashi, S., Ojima, A., Taniguchi, T., Miyamoto, N., Nakamori, C.,.. Sawada, K., Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes. Journal of Pharmacological and Toxicological Methods 75 (2015), 17–26, 10.1016/j.vascn.2015.04.002.
4. Belardinelli, L., Shryock, J.C., Fraser, H., Inhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazine. Heart 92 (2006), iv6–iv14.
5. Clements, M., Thomas, N., High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicological Sciences 140 (2014), 445–461, 10.1093/toxsci/kfu084.
6. Crumb, W., Vicente, J., Johannesen, L., Strauss, D.G., An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay ion channel panel. Journal of Pharmacological and Toxicological Methods 81 (2016), 251–262.
7. Di Veroli, G.Y., Davies, M.R., Zhang, H., Abi-Gerges, N., Boyett, M.R., High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment. American Journal of Physiology - Heart and Circulatory Physiology 304 (2013), H104–H117, 10.1152/ajpheart.00511.2012.
8. Di Veroli, G.Y., Davies, M.R., Zhang, H., Abi-Gerges, N., Boyett, M.R., hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: Implications for drug safety assessment. Journal of Cardiovascular Electrophysiology 25 (2014), 197–207, 10.1111/jce.12289.
9. Gilchrist, K.H., Lewis, G.F., Gay, E.A., Sellgren, K.L., Grego, S., High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays. Toxicology and Applied Pharmacology 288 (2015), 249–257, 10.1016/j.taap.2015.07.02.
10. Gintant, G., Sager, P.T., Stockbridge, N., Evolution of strategies to improve preclinical cardiac safety testing. Nature Reviews Drug Discovery, 2016, 10.1038/nrd.2015.34.
11. Harris, K., Aylott, M., Cui, Y., Louttit, J.B., McMahon, N.C., Sridhar, A., Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicological Sciences 134 (2013), 412–426, 10.1093/toxsci/kft113.
12. Hayakawa, T., Kunihiro, T., Ando, T., Kobayashi, S., Matsui, E., Yada, H.,.. Furukawa, T., Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. Journal of Molecular and Cellular Cardiology 77 (2014), 178–191, 10.1016/j.yjmcc.2014.09.010.
13. January, C.T., Riddle, J.M., Early afterdepolarizations: Mechanism of induction and block. A role for L-type Ca2 + current. Circulation Research 64 (1989), 977–990.
14. Johannesen, L., Vicente, J., Mason, J., Sanabria, C., Waite-Labott, K., Hong, M.,.. Strauss, D.G., Differentiating drug-induced multi-channel block on the electrocardiogram: Randomized study of dofetilide, quinidine, ranolazine and verapamil. Clinical Pharmacology and Therapeutics 96 (2014), 549–558, 10.1038/clpt.2014.155.
15. Johannesen, L., Vicente, J., Mason, J.W., Erato, C., Sanabria, C., Waite-Labott, K.,.. Strauss, D.G., Late sodium current block for drug-induced long QT syndrome: Phase 1 clinical trial and mechanistic investigation. Clinical Pharmacology and Therapeutics 99 (2016), 214–223, 10.1002/cpt.205.
16. + channel blocking drugs. PloS One, 11, 2016, e0149198, 10.1371/journal.pone.0149198.
17. Kirsch, G.E., Trepakova, E.S., Brimecombe, J.C., Sidach, S.S., Erickson, H.D., Kochan, M.C.,.. Brown, A.M., Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern. Journal of Pharmacological and Toxicological Methods 50 (2004), 93–101, 10.1016/j.vascn.2004.06.003.
18. Kitaguchi, T., Moriyama, Y., Taniguchi, T., Ojima, A., Ando, H., Uda, T.,.. Miyamoto, N., CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia — Effects of 7 reference compounds at 10 facilities. Journal of Pharmacological and Toxicological Methods 78 (2016), 93–102, 10.1016/j.vascn.2015.12.002.
19. Ks increases short-term QT interval variability and provokes torsades de pointes. British Journal of Pharmacology 151 (2007), 941–951, 10.1038/sj.bjp.0707297.
20. Li, Z., Dutta, S., Colatsky, T.J., A temperature-dependent computational ion channel model for human ether-a`-go-go-related gene. 2016, Journal of Pharmacological and Toxicological Methods (Accepted).
21. Liu, J., Laksman, Z., Backx, P.H., The electrophysiological development of cardiomyocytes. Advanced Drug Delivery Reviews 96 (2016), 253–273, 10.1016/j.addr.2015.12.023.
22. 2 + dynamics in human stem cell-derived cardiomyocytes by kinetic image cytometery: A cardiac risk assessment characterization using a large panel of cardioactive and inactive compounds. Toxicological Sciences 148 (2015), 503–516, 10.1016/j.vascn.2012.08.167.
23. Milnes, J.T., Witchel, H.J., Leaney, J.L., Leishman, D.J., Hancox, J.C., Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide. Journal of Pharmacological and Toxicological Methods 61 (2010), 178–191, 10.1016/j.vascn.2010.02.007.
24. Moreau, A., Krahn, A.D., Gosselin-Badaroudine, P., Klein, G.J., Christé, G., Vincent, Y.,.. Chahine, M., Sodium overload due to a persistent current that attenuates the arrhythmogenic potential of a novel LQT3 mutation. Frontiers in Pharmacology, 4, 2013, 126, 10.3389/fphar.2013.00126.
25. Nakamura, Y., Matsuo, J., Miyamoto, N., Ojima, A., Ando, K., Kanda, Y.,.. Sekino, Y., Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: Multi-site validation study. Journal of Pharmacological Sciences 124 (2014), 494–501, 10.1254/jphs.13248FP.
26. Nozaki, Y., Honda, Y., Tsujimoto, S., Watanabe, H., Kunimatsu, T., Funabashi, H., Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation. Toxicology and Applied Pharmacology 278 (2014), 72–77, 10.1016/j.taap.2014.04.007.
27. O'Hara, T., Rudy, Y., Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species. American Journal of Physiology - Heart and Circulatory Physiology 302 (2012), H1023–H1030, 10.1152/ajpheart.00785.2011.
28. O'Hara, T., Virag, L., Varró, A., Rudy, Y., Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation. PLoS One Computational Biology, 7, 2011, e1002061, 10.1371/journal.pcbi.1002061.
29. Polak, S., Pugsley, M.K., Stockbridge, N., Garnett, C., Wisniowska, B., Early drug discovery prediction of proarrhythmia potential and its covariates. The AAPS Journal 17 (2015), 1025–1032, 10.1208/s12248-015-9773-1.
30. Rampe, D., Brown, A.M., A history of the role of the hERG channel in cardiac risk assessment. Journal of Pharmacological and Toxicological Methods 68 (2013), 13–22, 10.1016/j.vascn.2013.03.005.
31. Sager, P.T., Gintant, G., Turner, J.R., Pettit, S., Stockbridge, N., Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the cardiac safety research consortium. American Heart Journal 167 (2014), 292–300, 10.1016/j.ahj.2013.11.004.
32. Ks) in canine ventricular myocytes. Journal of Physiology 551 (2003), 777–786, 10.1113/jphysiol.2003.044040.
33. Uesugi, M., Ojima, A., Taniguchi, T., Miyamoto, N., Sawada, K., Low-density plating is sufficient to induce cardiac hypertrophy and electrical remodeling in highly purified human iPS cell-derived cardiomyocytes. Journal of Pharmacological and Toxicological Methods 69 (2014), 177–188, 10.1016/j.vascn.2013.11.002.
34. van den Heuvel, N.H., van Veen, T.A., Lim, B., Jonsson, M.K., Lessons from the heart: Mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes. Journal of Molecular and Cellular Cardiology, 67, 2014, 12, 10.1016/j.yjmcc.2013.12.011.
35. Varró, A., Baczkó, I., Cardiac ventricular repolarization reserve: A principle for understanding drug-related proarrhythmic risk. British Journal of Pharmacology 164 (2011), 14–36, 10.1111/j.1476-5381.2011.01367.x.
36. Vicente, J., Johannesen, L., Mason, J.W., Pueyo, E., Stockbridge, N., Strauss, D.G., Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine and verapamil. Journal of the American Heart Association, 13, 2015, e001615, 10.1161/JAHA.114.001615.
37. Virág, L., Acsai, K., Hála, O., Zaza, A., Bitay, M., Bogáts, G., Papp, J.G.Y., Self-augmentation of the lengthening of repolarization is related to the shape of the cardiac action potential: Implications for reverse rate dependency. British Journal of Pharmacology 156 (2009), 1076–1084, 10.1111/j.1476-5381.2009.00116.x.
38. + current reduction prolongs action potentials and promotes afterdepolarisations: A dynamic-clamp study in human and rabbit cardiac atrial myocytes. Journal of Physiology 590 (2012), 4289–4305, 10.1113/jphysiol.2012.235986.
39. Yao, J.A., Du, X., Lu, D., Baker, R.L., Daharsh, E., Atterson, P., Estimation of potency of HERG channel blockers: Impact of voltage protocol and temperature. Journal of Pharmacological and Toxicological Methods 52 (2005), 146–153, 10.1016/j.vascn.2005.04.008.
40. Matsuo, J., Nakamura, Y., Izumi-Nakaseko, H., Ando, K., Sekino, Y., Sugiyama, A., Possible effects of inhibition of IKr and IKs on field-potential waveforms in the human iPS cell-derived cardiomyocytes sheet. Journal of Pharmacological Sciences 128 (2015), 92–95, 10.1016/j.jphs.2015.05.004.